David Givol
Overview
Explore the profile of David Givol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1641
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amsterdam A, Raanan C, Polin N, Melzer E, Givol D, Schreiber L
Acta Histochem
. 2013 Aug;
116(1):197-203.
PMID: 23978330
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers because of late symptoms and resistance to chemotherapy and radiation therapy. We have investigated the appearance of c-kit, a...
2.
Amsterdam A, Raanan C, Schreiber L, Polin N, Givol D
Biochem Biophys Res Commun
. 2013 Feb;
433(2):157-62.
PMID: 23438436
Pancreas cancer, is the fourth leading cause of cancer death but its cell of origin is controversial. We compared the localization of stem cells in normal and cancerous pancreas using...
3.
Amsterdam A, Raanan C, Schreiber L, Freyhan O, Fabrikant Y, Melzer E, et al.
Acta Histochem
. 2012 Oct;
115(4):320-9.
PMID: 23098761
One paradigm of cancer development claims that cancer emerges at the niche of tissue stem cells and these cells continue to proliferate in the tumor as cancer stem cells. LGR5,...
4.
Amsterdam A, Raanan C, Schreiber L, Freyhan O, Schechtman L, Givol D
Acta Histochem
. 2012 Oct;
115(4):330-8.
PMID: 23092806
LGR5 and Nanog were recently characterized as stem cell markers in various embryonic, adult and cancer stem cells. However, there are no data on their precise localization in the normal...
5.
6.
Nodale C, Sheffer M, Jacob-Hirsch J, Folgiero V, Falcioni R, Aiello A, et al.
Cancer Biol Ther
. 2012 Jan;
13(4):198-205.
PMID: 22236966
Vimentin, a mesenchymal marker, is frequently overexpressed in epithelial carcinomas undergoing epithelial to mesenchymal transition (EMT), a condition correlated with invasiveness and poor prognosis. Therefore, vimentin is a potential molecular...
7.
Sheffer M, Simon A, Jacob-Hirsch J, Rechavi G, Domany E, Givol D, et al.
Oncotarget
. 2011 Dec;
2(12):1191-202.
PMID: 22202117
Hypoxia-inducible factor 1 (HIF-1), the major transcription factor specifically activated during hypoxia, regulates genes involved in critical aspects of cancer biology, including angiogenesis, cell proliferation, glycolysis and invasion. The HIF-1a...
8.
Margalit O, Simon A, Yakubov E, Puca R, Yosepovich A, Avivi C, et al.
Int J Cancer
. 2011 Sep;
131(4):E562-8.
PMID: 21932419
Activated p53 is necessary for tumor suppression. Homeodomain-interacting protein kinase-2 (HIPK2) is a positive regulator of functional p53. HIPK2 modulates wild-type p53 activity toward proapoptotic transcription and tumor suppression by...
9.
Puca R, Nardinocchi L, Porru M, Simon A, Rechavi G, Leonetti C, et al.
Cell Cycle
. 2011 Apr;
10(10):1679-89.
PMID: 21508668
Absence of p53 expression or expression of mutant p53 (mtp53) are common in human cancers and are associated with increased cancer resistance to chemo- and radiotherapy. Therefore, significant efforts towards...
10.
Nardinocchi L, Pantisano V, Puca R, Porru M, Aiello A, Grasselli A, et al.
PLoS One
. 2010 Dec;
5(12):e15048.
PMID: 21179202
Background: Hypoxia inducible factor-1α (HIF-1α) is responsible for the majority of HIF-1-induced gene expression changes under hypoxia and for the "angiogenic switch" during tumor progression. HIF-1α is often upregulated in...